Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fecal Microbiota Transplantation for Primary Sclerosing Cholangitis
NCT07477782Phase 2Not yet recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- May 2026
- Primary completion
- Apr 2029
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 2, randomised trial of Fecal Microbiota Transplantation Capsule in Primary Sclerosing Cholangitis (PSC) (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Alkaline Phosphatase and Bilirubin Levels at 48 weeks. Planned start May 2026; status: not yet recruiting.
02
Drugs
Fecal Microbiota Transplantation Capsule
03
Conditions
Primary Sclerosing Cholangitis (PSC)
Beyond the preview
Go deeper on NCT07477782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07477782.